Anxioselective anxiolytics: on a quest for the Holy Grail.

[1]  Chris de Graaf,et al.  Diazepam-bound GABAA receptor models identify new benzodiazepine binding-site ligands. , 2012, Nature chemical biology.

[2]  A. Abbott.  Novartis to shut brain research facility , 2011, Nature.

[3]  G. Bormans,et al.  MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans , 2011, Journal of psychopharmacology.

[4]  Sandra M. Sanabria-Bohórquez,et al.  Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist , 2011, Journal of psychopharmacology.

[5]  P. Czobor,et al.  A Multicenter, Placebo‐Controlled, Double‐Blind, Randomized Study of Efficacy and Safety of Ocinaplon (DOV 273,547) in Generalized Anxiety Disorder , 2010, CNS neuroscience & therapeutics.

[6]  R. Ramakrishnan,et al.  Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA α2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers , 2008, Journal of psychopharmacology.

[7]  J. Gerven,et al.  Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers , 2007 .

[8]  William J. A. Eiler,et al.  Dopaminergic and GABAergic Regulation of Alcohol-Motivated Behaviors: Novel Neuroanatomical Substrates , 2007 .

[9]  D. Farb,et al.  Pharmacology of the GABAA Receptor , 2007 .

[10]  D. Nutt,et al.  Pharmacotherapy of anxiety. , 2007, Handbook of experimental pharmacology.

[11]  G. Dawson,et al.  Evidence for a Significant Role of α3-Containing GABAA Receptors in Mediating the Anxiolytic Effects of Benzodiazepines , 2005, The Journal of Neuroscience.

[12]  P. Czobor,et al.  Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  H. Mohler,et al.  Analysis of the Presence and Abundance of GABAA Receptors Containing Two Different Types of α Subunits in Murine Brain Using Point-mutated α Subunits* , 2004, Journal of Biological Chemistry.

[14]  E. Sigel,et al.  Positioning of the α-subunit isoforms confers a functional signature to γ-aminobutyric acid type A receptors , 2004 .

[15]  I. Tobler,et al.  Modulation of rhythmic brain activity by diazepam: GABA(A) receptor subtype and state specificity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[17]  R. Gieschke,et al.  Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. , 2003, British journal of clinical pharmacology.

[18]  J. Davidson,et al.  Pregabalin in generalized anxiety disorder: a placebo-controlled trial. , 2003, The American journal of psychiatry.

[19]  S. Stahl.  Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. , 2002, The Journal of clinical psychiatry.

[20]  J. Hoyer,et al.  Generalized anxiety disorder: nature and course. , 2001, The Journal of clinical psychiatry.

[21]  Irene Tobler,et al.  Diazepam-induced changes in sleep: Role of the α1 GABAA receptor subtype , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Adkins,et al.  Effect of α Subunit on Allosteric Modulation of Ion Channel Function in Stably Expressed Human Recombinant γ-Aminobutyric AcidA Receptors Determined Using36Cl Ion Flux , 2001 .

[23]  M. Pollack,et al.  Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. , 2001, The Journal of clinical psychiatry.

[24]  M. Mandelli,et al.  Molecular targets for the myorelaxant action of diazepam. , 2001, Molecular pharmacology.

[25]  T. Rülicke,et al.  Molecular and neuronal substrate for the selective attenuation of anxiety. , 2000, Science.

[26]  R. Mckernan,et al.  Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype , 2000, Nature Neuroscience.

[27]  J. Benson,et al.  erratum: Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes , 2000, Nature.

[28]  G. Griebel,et al.  Beta-CCT, a selective BZ-omega1 receptor antagonist, blocks the anti-anxiety but not the amnesic action of chlordiazepoxide in mice. , 2000, Behavioural pharmacology.

[29]  G. Griebel,et al.  β‐CCT, a selective BZ‐ω1 receptor antagonist, blocks the anti‐anxiety but not the amnesic action of chlordiazepoxide in mice , 2000 .

[30]  J. Benson,et al.  Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes , 1999, Nature.

[31]  B. Aufdembrinke.  Abecarnil, a new beta-carboline, in the treatment of anxiety disorders , 1998, British Journal of Psychiatry.

[32]  E A Barnard,et al.  International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. , 1998, Pharmacological reviews.

[33]  M. Hascöet,et al.  Anticonflict Effect of Alpidem as Compared with the Benzodiazepine Alprazolam in Rats , 1997, Pharmacology Biochemistry and Behavior.

[34]  F. Besnard,et al.  Pharmacological profile of benzodiazepine site ligands with recombinant GABAA receptor subtypes , 1996, European Neuropsychopharmacology.

[35]  R. Mckernan,et al.  Which GABAA-receptor subtypes really occur in the brain? , 1996, Trends in Neurosciences.

[36]  P. Rosenzweig,et al.  Assessment of the interaction between a partial agonist and a full agonist of benzodiazepine receptors, based on psychomotor performance and memory, in healthy volunteers , 1995, Journal of psychopharmacology.

[37]  G. Perrault,et al.  Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: Evidence for the functional significance of receptor subtypes , 1994, Neuroscience & Biobehavioral Reviews.

[38]  B. J. Cole,et al.  Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: an analysis based on fractional receptor occupancies , 1994, Psychopharmacology.

[39]  D. Carter,et al.  Potentiation of gamma-aminobutyric acid-induced chloride currents by various benzodiazepine site agonists with the alpha 1 gamma 2, beta 2 gamma 2 and alpha 1 beta 2 gamma 2 subtypes of cloned gamma-aminobutyric acid type A receptors. , 1993, Molecular pharmacology.

[40]  G. Perrault,et al.  Repeated treatment with alpidem, a new anxiolytic, does not induce tolerance or physical dependence , 1993, Neuropharmacology.

[41]  P. Rosenzweig,et al.  Alpidem: Lack of sedative effect on psychomotor performance in therapeutic doses , 1993 .

[42]  C. Faure-Halley,et al.  Expression and properties of recombinant α1β2γ2 and α5β2γ2 forms of the rat GABAA receptor , 1993 .

[43]  J. Kemp,et al.  Functional comparison of the role of gamma subunits in recombinant human gamma-aminobutyric acidA/benzodiazepine receptors. , 1993, Molecular pharmacology.

[44]  T. Duka,et al.  Human studies on abecarnil a new beta-carboline anxiolytic: safety, tolerability and preliminary pharmacological profile. , 1993, British journal of clinical pharmacology.

[45]  E. Costa,et al.  Triazolam is more efficacious than diazepam in a broad spectrum of recombinant GABAA receptors. , 1993, European journal of pharmacology.

[46]  W Wisden,et al.  The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[47]  P. Seeburg,et al.  A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. , 1992, The Journal of biological chemistry.

[48]  G. Perrault,et al.  Alpidem, an omega-1 receptor-selective partial agonist: a new approach to anxiety treatment , 1991, European Neuropsychopharmacology.

[49]  W. Haefely,et al.  Novel anxiolytics that act as partial agonists at benzodiazepine receptors. , 1990, Trends in pharmacological sciences.

[50]  G. Perrault,et al.  Pharmacological and Behavioral Profile of Alpidem as an Anxiolytic , 1990, Pharmacopsychiatry.

[51]  M. Lader,et al.  Studies with alpidem in normal volunteers and anxious patients. , 1990, Pharmacopsychiatry.

[52]  D. Stephens,et al.  Abecarnil, a metabolically stable, anxioselective beta-carboline acting at benzodiazepine receptors. , 1990, The Journal of pharmacology and experimental therapeutics.

[53]  P. Seeburg,et al.  Two novel GABAA receptor subunits exist in distinct neuronal subpopulations , 1989, Neuron.

[54]  P. Morselli,et al.  Clinical studies with the new anxiolytic alpidem in anxious patients: An overview of the European experiences , 1988, Pharmacology Biochemistry and Behavior.

[55]  P. Seeburg,et al.  Sequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-family , 1987, Nature.

[56]  H. Shannon,et al.  beta-Carboline-3-carboxylate-t-butyl ester: a selective BZ1 benzodiazepine receptor antagonist. , 1984, Life sciences.

[57]  B. Beer,et al.  Molecular substrates of anxiety: clues from the heterogeneity of benzodiazepine receptors. , 1982, Life sciences.

[58]  B. Beer,et al.  The role of GABA in mediating the anticonvulsant properties of benzodiazepines , 1980, Brain Research Bulletin.

[59]  S. Paul,et al.  Receptors for the age of anxiety: pharmacology of the benzodiazepines. , 1980, Science.

[60]  B. Beer,et al.  A synthetic non-benzodiazepine ligand for benzodiazepine receptors: A probe for investigating neuronal substrates of anxiety , 1979, Pharmacology Biochemistry and Behavior.

[61]  B. Beer,et al.  Benzodiazepine receptors: Cellular and behavioral characteristics , 1979, Pharmacology Biochemistry and Behavior.

[62]  B. Beer,et al.  Relationship between benzodiazepine receptors and experimental anxiety in rats , 1978, Pharmacology Biochemistry and Behavior.

[63]  H. Mohler,et al.  Benzodiazepine receptor: demonstration in the central nervous system , 1977, Science.

[64]  G. Fischbach,et al.  Chlordiazepoxide selectively augments GABA action in spinal cord cell cultures , 1977, Nature.

[65]  C. Braestrup,et al.  Benzodiazepine receptors in rat brain , 1977, Nature.

[66]  J. Atack.  Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023. , 2009, Advances in pharmacology.

[67]  B. Beer,et al.  A simple and reliable conflict procedure for testing anti-anxiety agents , 2004, Psychopharmacologia.

[68]  J. Castaǹer,et al.  Ocinaplon: Treatment of generalized anxiety disorder GABAAreceptor modulator , 2003 .

[69]  J. Fritschy,et al.  A new benzodiazepine pharmacology. , 2002, The Journal of pharmacology and experimental therapeutics.

[70]  M. Pollack,et al.  Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. , 1997, The Journal of clinical psychiatry.

[71]  B. Denis,et al.  Hépatite imputable à l'alpidem (Ananxyl®) : quatre cas dont un mortel , 1994 .

[72]  B. Denis,et al.  [Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal]. , 1994, Gastroenterologie clinique et biologique.

[73]  D. Stephens,et al.  Abecarnil is a full agonist at some, and a partial agonist at other recombinant GABAA receptor subtypes. , 1993, Psychopharmacology series.

[74]  P. Skolnick.  Is Receptor Heterogeneity Relevant to the Anxiolytic Actions of Benzodiazepine Receptor Ligands , 1991 .

[75]  J. Bénavidès,et al.  Zolpidem and alpidem: two imidazopyridines with selectivity for omega 1- and omega 3-receptor subtypes. , 1990, Advances in biochemical psychopharmacology.

[76]  S. Z. Langer.  Zolpidem and Alpidem : Two imidazopyridines with selectivity for ω_1-and ω_3-receptor subtypes , 1990 .